The 15% p.a. return that is helping drive interest in BB Biotech

Head of Investment at BB Biotech, Daniel Koller, discusses sector growth and the attractive valuations of fast growing companies.

Partner insight Over the last five to ten years, the biotech sector has seen compelling returns and BB Biotech - one of the largest biotech investors in Europe - is among the positive performers. The group target an annual return of 15% and investors also receive a dividend yield of 5% per annum. The reality of drug development programmes is that the pipelines are lengthy and clinical setbacks are common, so Koller says investors should "assess risk at the individual level and recognise that different medical indications represent different risks." Often, investors will consider risk ...